In CRC, immune checkpoint inhibitors (ICIs) such as PD-1 and PD-L1 antibodies show poor response, suggesting that other immune checkpoints should be targeted to achieve clinical benefits. This evidence concerns the gene PDCD1 and colorectal carcinoma.